[{"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "9644.49", "Date_of_Payment": "08/22/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "106110961", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "514.65", "Date_of_Payment": "09/25/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106111712", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "187.50", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106111715", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "109.50", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106111714", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "93.75", "Date_of_Payment": "09/25/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106111713", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "21.90", "Date_of_Payment": "10/30/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106111707", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "117286", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "21.90", "Date_of_Payment": "12/22/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106111711", "Name_of_Associated_Covered_Drug_or_Biological1": "Uloric", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia", "Research_Information_Link": "", "Context_of_Research": ""}]